US 7939562B2
· Grinberg et al.
· 2011
[cited by applicant]
US 9629929B2
· Lötvall et al.
· 2017
[cited by applicant]
US 9858477B2
· Nakamura et al.
· 2018
[cited by applicant]
US 20080268542A1
· Rubio et al.
· 2008
[cited by applicant]
US 20170340563A1
· Javeri et al.
· 2017
[cited by applicant]
US 20190175506A1
· Noyes et al.
· 2019
[cited by applicant]
WO 2000054057A1
· 2000
[cited by applicant]
WO 2013059343A1
· 2013
[cited by applicant]
WO 2013070324A1
· 2013
[cited by applicant]
WO 2016077639A2
· 2016
[cited by applicant]
WO 2016168680A1
· 2016
[cited by applicant]
WO 2017004526A1
· 2017
[cited by applicant]
WO 2017161010A1
· 2017
[cited by applicant]
Jo et al. Nanoscale, 2014, 6, 12056-12064.
[cited by examiner]
Su, Yang. Microfluidics. Creating Nanoparticles with Microfluidizer High-Shear fluid Technology available on Jan. 11, 2017 at https://static.horiba.com/fileadmin/Horiba/Products/Scientific/Particle_Characterization/Webi…
[cited by examiner]
O'dea et al. PLoS One. 2017; 12(3): e0174779 Mar. 30, 2017.
[cited by examiner]
How do you convert from %w/v to molarity retrieved from https://How do you convert from %“w/v” to molarity? + Example (socratic.org) retrieved Jul. 10, 2024.
[cited by examiner]
“C12H22O11 (Sucrose) Molar Mass” retrieved from ttps://www.chemicalaid.com/tools/molarmass.php?formula=C12H22O11&hl=en retrieved Jul. 10, 2024.
[cited by examiner]
Ambardekar et al. Biomaterials. Feb. 2011; 32(5): 1404-141.
[cited by examiner]
Bosch et al., “Trehalose prevents aggregation of exosomes and cryodamage,” Science Report 6: 36162 (2016).
[cited by applicant]
Burdette et al., “STING is a direct innate immune sensor of cyclic di-GMP,” Nature 478(7370):515-518 (2012).
[cited by applicant]
Jo et al., “Large-scale generation of cell-derived nanovesicles,” Nanoscale 6(20): 12056-12064 (2014).
[cited by applicant]
Kamerkar et al., “Exosomes facilitate therapeutic targeting of oncogenic Kras in pancreatic cancer,” Nature 546(7659):498-503 (2017).
[cited by applicant]
Li et al., “Hydrolysis of 2′3′-cGAMP by ENPPI and design of nonhydrolyzable analogs,” Nature Chemical Biology 10(12):1043-1048 (2014).
[cited by applicant]
M-110EH-30 Microfluidizer™ Processor, Microfluidics (2012), accessed at chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://wolfson.huji.ac.il/purification/pictures/Microfluidics_microfluidizer_modelM110EHIS%29.…
[cited by applicant]
Martineau et al., “Expression of an antibody fragment at high levels in the NPL6 bacterial cytoplasm,” Journal of Molecular Biology 280(1):117-127 (1998).
[cited by applicant]
Miryabe et al., “A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy,” Journal of Controlled Release 184: 20-27 (2014).
[cited by applicant]
“Recipe: Phosphate Buffered Saline,” (2006) Cold Spring Harbor Protocols, accessed at http://cshprotocols.cshlp.org/content/2006/l/pdb.rec8247 on Dec. 4, 2019, 1 page.
[cited by applicant]
Sharei et al., “A vector-free microfluidic platform for intracellular delivery,” Proc Natl Acad Sci USA 110(6):2082-2087 (2013).
[cited by applicant]
Stewart et al., “In vitro and ex vivo strategies for intracellular delivery,” Nature 538(7624):183-192 (2016).
[cited by applicant]
Sutaria et al., “Achieving the promise of therapeutic extracellular vesicles: the devil is in details of therapeutic loading,” Pharm Res. 34(5): 1053-1066 (2017).
[cited by applicant]
Visintin et al., “Selection of antibodies for intracellular function using a two-hybrid in vivo system,” Proc Natl Acad Sci USA 96(21): 11723-11728 (1999).
[cited by applicant]
Wahlgren et al., “Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes,” Nucleic Acids Research 40(17): e130 (2012).
[cited by applicant]
Whitehead et al., “Knocking down barriers: advances in siRNA delivery,” Nature Reviews Drug Discovery 8(2): 129-138 (2009).
[cited by applicant]
Zhang et al., “Microvesicle-mediated delivery of transforming growth factor beta-1 siRNA for the suppression of tumor growth in mice,” Biomaterials 35(14):4390-400 (2014).
[cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action in U.S. Appl. No. 16/190,058, dated Dec. 9, 2019.
[cited by applicant]
United States Patent and Trademark Office, Final Office Action in U.S. Appl. No. 16/190,058, dated May 7, 2020.
[cited by applicant]
United States Patent and Trademark Office, Notice of Abandonment in U.S. Appl. No. 16/190,058, dated Nov. 25, 2020.
[cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action in U.S. Appl. No. 17/014,961, dated Dec. 21, 2021.
[cited by applicant]
United States Patent and Trademark Office, Final Office Action in U.S. Appl. No. 17/014,961, dated Jun. 8, 2022.
[cited by applicant]
United States Patent and Trademark Office, Notice of Abandonment in U.S. Appl. No. 17/014,961, dated Jan. 4, 2023.
[cited by applicant]